Table 5.
Specific types of surgery, reconstruction surgeries, and timing to chemotherapy or endocrine therapy that compose treatment regimens for patients with breast cancer
| Patient Characteristics | Center A Pre-COVID N= 123 | Center A COVID N= 25 | Center B Pre-COVID N= 58 | Center B COVID N= 0 | Center C Pre-COVID N= 92 | Center C COVID N= 16 | Center D Pre-COVID N= 80 | Center D COVID N= 10 | p-value |
|---|---|---|---|---|---|---|---|---|---|
| Primary surgery (n (%) ) | NA | ||||||||
| Lumpectomy | 40 (32.5%) | 13 (52.0%) | 33 (58.9%) | - | 23 (25.0%) | 7 (50.0%) | 42 (53.8%) | 4 (40.0%) | |
| Mastectomy | 0 (0.0%) | 0 (0.0%) | 1 (1.8%) | - | 3 (3.3%) | 0 (0.0%) | 2 (2.6%) | 0 (0.0%) | |
| Modified Radical Mastectomy | 11 (8.9%) | 5 (20.0%) | 0 (0.0%) | – | 22 (23.9%) | 0 (0.0%) | 9 (11.5%) | 1 (10.0%) | |
| No Surgery | 7 (5.7%) | 1 (4.0%) | 8 (14.3%) | – | 18 (19.6%) | 1 (7.1%) | 9 (11.5%) | 0 (0.0%) | |
| Pending | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (10.0%) | |
| Radical Mastectomy | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – | 1 (1.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Re-excision of biopsy site | 21 (17.1%) | 0 (0.0%) | 2 (3.6) | – | 9 (9.8%) | 0 (0.0%) | 6 (7.7%) | 0 (0.0%) | |
| Simple Mastectomy | 44 (35.8%) | 6 (24.0%) | 12 (21.4) | – | 16 (17.4%) | 6 (42.9%) | 10 (12.8%) | 4 (40.0%) | |
| Reconstruction (n (%)) | |||||||||
| Combined | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – | 0 (0.0%) | 0 (0.0%) | 3 (4.9%) | 0 (0.0%) | |
| Implant | 28 (26.4%) | 4 (16.7%) | 0 (0.0%) | – | 2 (2.2%) | 0 (0.0%) | 0 (0.0%) | 1 (10.0%) | |
| None | 70 (66.0%) | 18 (75.0%) | 43 (93.5%) | – | 84 (94.4%) | 12 (100.0) | 58 (95.1%) | 9 (90.0%) | |
| Tissue | 8 (7.5%) | 2 (8.3%) | 3 (6.5%) | 3 (3.4%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
| Treatment delayed (n (%) | – | 15 (60.0) | 0 (NaN) | – | – | 9 (56.2) | - | 4 (40.0) | NA |
| Neoadjuvant therapy (n (%) | 28 (23.5) | 10 (40.0) | 14 (25.0) | – | 20 (23.0) | 8 (50.0) | 5 (6.5) | 6 (60.0) | NA |
| Adjuvant therapy (n (%) | 23 (19.3) | 9 (40.9) | 9 (16.1) | – | 16 (18.4) | 2 (20.0) | 17 (22.1) | 7 (70.0) | NA |
| Adjuvant radiation (n (%) | 65 (53.3) | 17 (77.3) | 34 (60.7) | – | 46 (50.5) | 6 (60.0) | 35 (44.3) | 5 (55.6) | NA |
| Time to surgery (median, days) | 57 | 51 | 64.5 | – | 83 | 64 | 42 | 129 | NA |
To further analyze for potential disparities, the pre-COVID and COVID cohorts were further stratified by treatment center to assess whether significant differences in treatment regimens existed across all hospitals